Cargando…
PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN
Targeting mutant BRAF in patients with melanomas harboring this oncogene has been highly successful as a first-line treatment, but other mutations may affect its efficacy and alter the route of acquired resistance resulting in recurrence and poor prognosis. As an evolving strategy, melanoma treatmen...
Autores principales: | Qin, Yifei, Zuo, Qiang, Huang, Lei, Huang, Liping, Merlino, Glenn, Yu, Yanlin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8289936/ https://www.ncbi.nlm.nih.gov/pubmed/34282258 http://dx.doi.org/10.1038/s41698-021-00207-x |
Ejemplares similares
-
PTEN phosphatase inhibits metastasis by negatively regulating the Entpd5/IGF1R pathway through ATF6
por: Yu, Yanlin, et al.
Publicado: (2023) -
PTEN Dual Lipid- and Protein-Phosphatase Function in Tumor Progression
por: Liu, Anne, et al.
Publicado: (2022) -
Notch Signaling Suppresses Melanoma Tumor Development in BRAF/Pten Mice
por: Mikheil, Dareen, et al.
Publicado: (2023) -
Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells
por: Garay, Tamás, et al.
Publicado: (2015) -
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)